title: Differential expression of testin and survivin in breast cancer subtypes.
abstract: Testin (TES) is a putative tumour-suppressor gene downregulated in various types of cancers. Survivin is a nodal protein involved in multiple signalling pathways, tumour maintenance and inhibition of apoptosis. Previous studies indicate that TES and survivin can functionally interact and modulate cell death and proliferation in breast cancer cells. The aim of the present study was to investigate the expression and prognostic relevance of TES and survivin in breast cancer subtypes examining a large cohort of breast cancer patients. We determined the expression of TES and survivin by immunohistochemistry (IHC) in tissue samples from 242 breast cancer patients diagnosed between 1981 and 2009. The expression of these proteins was compared with clinical and pathological data. There was a significant association of nuclear survivin overexpression and TES downregulation with triple-negative tumours [P=0.009; univariate odds ratio (OR), 3.20; 95% CI, 1.34-7.66] (P=0.018; multivariate OR, 2.90; 95% CI, 1.20‑6.97). A further significant correlation was observed between TES downregulation and the luminal B subtype (P=0.019, univariate OR: 2.90; 95% CI, 1.19‑7.06) (P=0.032, multivariate OR, 2.67; 95% CI, 1.09-6.65), independent of survivin expression. Our results demonstrated a statistically significant association between TES downregulation and highly aggressive breast tumour subtypes, such as triple-negative and luminal B tumours, along with the prognostic relevance of nuclear expression of survivin. To our knowledge, this is the first demonstration of such an association.
authors.affiliation: Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland. manuela.sarti@eoc.ch
authors.forename: Manuela
authors.initials: M
authors.lastname: Sarti
authors.forename: Sandra
authors.initials: S
authors.lastname: Pinton
authors.forename: Costanzo
authors.initials: C
authors.lastname: Limoni
authors.forename: Giuseppina M
authors.initials: GM
authors.lastname: Carbone
authors.forename: Olivia
authors.initials: O
authors.lastname: Pagani
authors.forename: Franco
authors.initials: F
authors.lastname: Cavalli
authors.forename: Carlo V
authors.initials: CV
authors.lastname: Catapano
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D003598:Cytoskeletal Proteins / Q000096:biosynthesis* / Q000235:genetics; D015536:Down-Regulation; D005260:Female; D015870:Gene Expression; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000096:biosynthesis* / Q000235:genetics; D060588:LIM Domain Proteins / Q000096:biosynthesis* / Q000235:genetics; D008875:Middle Aged; D011379:Prognosis; D016601:RNA-Binding Proteins; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D003598:Cytoskeletal Proteins; D051034:Inhibitor of Apoptosis Proteins; D060588:LIM Domain Proteins; D016601:RNA-Binding Proteins; D000077022:Survivin; C429688:TES protein, human